What does CUSIP 86150R107 represent in this 13F holders report?

CUSIP 86150R107 is the security identifier for STOK - Stoke Therapeutics, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held STOK - Stoke Therapeutics, Inc. - Common Stock in Q2 2019?

47 institutional investors reported STOK - Stoke Therapeutics, Inc. - Common Stock for Q2 2019. Use the holders table for investor-level position and value details.

Stoke Therapeutics, Inc. - Common Stock (STOK)

CUSIP: 86150R107

Q2 2019 13F Holders as of 30 Jun 2019

Type / Class: Equity / Common Stock
Shares outstanding: 57,529,259
Total 13F shares: 14,232,528
Share change: +14,232,528
Total reported value: $409,341,450
Price per share: $29.17
Number of holders: 47
Value change: +$409,341,450
Number of buys: 47

Quarterly Holders Quick Answers

What is CUSIP 86150R107?
CUSIP 86150R107 identifies STOK - Stoke Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2019

Recent filing periods for CUSIP 86150R107:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of STOK - Stoke Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.

Institutional Holders of Stoke Therapeutics, Inc. - Common Stock (STOK) as of Q2 2019

As of 30 Jun 2019, Stoke Therapeutics, Inc. - Common Stock (STOK) was held by 47 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 14,232,528 shares. The largest 10 holders included RTW INVESTMENTS, LP, Cormorant Asset Management, LP, GILDER GAGNON HOWE & CO LLC, RA CAPITAL MANAGEMENT, LLC, Redmile Group, LLC, PERCEPTIVE ADVISORS LLC, FMR LLC, MILLENNIUM MANAGEMENT LLC, WELLINGTON MANAGEMENT GROUP LLP, and JANUS HENDERSON GROUP PLC. This page lists 47 institutional shareholders reporting positions in this security for the Q2 2019 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2019 vs Q4 2025 Across Filers

Q4 2025 holders

181

Q2 2019 holders

Holder diff

-134

Investor	Q4 2025 Shares	Q2 2019 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q2 2019 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.